Vivimed Labs is currently trading at Rs. 309.80, up by 15.60 points or 5.30% from its previous closing of Rs. 294.20 on the BSE.
The scrip opened at Rs. 300.10 and has touched a high and low of Rs. 315.20 and Rs. 300.00 respectively. So far 82068 shares were traded on the counter.
The BSE group 'B ' stock of face value Rs. 10 has touched a 52 week high of Rs. 435.40 on 01-Dec-2014 and a 52 week low of Rs. 175.00 on 24-Jun-2015.
Last one week high and low of the scrip stood at Rs. 315.20 and Rs. 262.00 respectively. The current market cap of the company is Rs. 502.32 crore.
The promoters holding in the company stood at 36.99% while Institutions and Non-Institutions held 27.69% and 35.32% respectively.
Vivimed Labs is planning to sell part of its specialty chemicals business to a strategic investor or special purpose vehicle (SPV) of the company or third party on slump sale basis for a consideration of not less than Rs 380 crore. In this regard, the company has received approval from its board at the meeting held on September 12, 2015, while the members’ approval will be taken through postal ballot
The company will sell the same with an aim to optimise the capital structure of the company and prepare for next leg of growth across its business units and post an ongoing review of the strategic options.
Vivimed Labs is a listed company engaged in the business of manufacturing products (active ingredients, formulations, etc) for pharmaceutical, personal care and colour chemistry industry. VLL (Consolidated) has manufacturing facilities in India and Overseas.
| Company Name | CMP |
|---|---|
| Sun Pharma. Inds. | 1882.65 |
| Dr. Reddys Labs. | 1357.00 |
| Cipla | 1441.85 |
| Zydus Lifesciences | 1106.50 |
| Lupin | 2369.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: